Malignant melanoma.
The papers reviewed in this chapter emphasise the continued difficulties in making progress with the management of advanced malignant melanoma. Data is consistently accrued to confirm the relatively favourable prognosis of thin lesions and hence the importance of early detection and educational programmes to help patients to seek medical assistance when early changes appear. The papers on regional perfusion show some encouraging results but for systemic metastases, cytotoxic drugs show very little if any true benefit. Conversely, the increased interest in biological response modifiers does hold out some genuine promise of being able to influence the course of this unpredictable and refractory malignant disease.
Smyth
J F
JF
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008545:Melanoma / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors